Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;21(2):64-8.
doi: 10.3747/co.21.1656.

A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers

S A Narod  1 , N Tung  2 , J Lubinski  3 , T Huzarski  3 , M Robson  4 , H T Lynch  5 , S L Neuhausen  6 , P Ghadirian  7 , C Kim-Sing  8 , P Sun  1 , W D Foulkes  9 ; Hereditary Breast Cancer Clinical Study Group
Affiliations

A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers

S A Narod et al. Curr Oncol. 2014 Apr.

Abstract

Background: The risk of breast cancer in carriers of BRCA1 and BRCA2 mutations is influenced by factors other than the genetic mutation itself. Modifying factors include a woman's reproductive history and family history of cancer. Risk factors are more likely to be present in women with breast cancer than in women without breast cancer, and therefore the risk of cancer in the two breasts should not be independent. It is not clear to what extent modifying factors influence the risk of a first primary or a contralateral breast cancer in BRCA carriers.

Methods: We conducted a matched case-control study of breast cancer among 3920 BRCA1 or BRCA2 mutation carriers. We asked whether a past history of breast cancer in the contralateral breast was a risk factor for breast cancer.

Results: After adjustment for age, country of residence, and cancer treatment, a previous cancer of the right breast was found to be a significant risk factor for cancer of the left breast among BRCA1 or BRCA2 carriers (relative risk: 2.1; 95% confidence interval: 1.4 to 3.0; p < 0.0001).

Conclusions: In a woman with a BRCA1 or BRCA2 mutation who is diagnosed with breast cancer, the risk of cancer in the contralateral breast depends on the first diagnosis. That observation supports the hypothesis that there are important genetic or non-genetic modifiers of cancer risk in BRCA carriers. Discovering risk modifiers might lead to greater personalization of risk assessment and management recommendations for BRCA-positive patients.

Keywords: BRCA1; BRCA2; contralateral breast cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30. doi: 10.1086/375033. - DOI - PMC - PubMed
    1. Narod SA, Finch A, Metcalfe K, et al. The impact of genetic testing and genetic counselling on the penetrance of breast and ovarian cancer in BRCA1 and BRCA2 carriers. J Clin Oncol. 2014 [in press]
    1. Metcalfe K, Lubinski J, Lynch HT, et al. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst. 2010;102:1874–8. doi: 10.1093/jnci/djq443. - DOI - PubMed
    1. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst. 2002;94:1221–6. doi: 10.1093/jnci/94.16.1221. - DOI - PubMed
    1. Jernström H, Lerman C, Ghadirian P, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999;354:1846–50. doi: 10.1016/S0140-6736(99)04336-6. - DOI - PubMed

LinkOut - more resources